Notice of Allowance received for combination of RedHill’s novel orally-administered investigational drugs, opaganib and RHB-107, for treatment of solid tumor cancers; patent expected to extend IP protection until 2036
Combination of opaganib and RHB-107 demonstrated potent antitumor effect and tumor regression in recent cholangiocarcinoma pre-clinical study
RedHill plans to add third cohort evaluating this combination to its ongoing Phase 2a study of opaganib in advanced cholangiocarcinoma, subject to FDA discussions
TEL AVIV, Israel and RALEIGH, N.C., Nov. 04, 2020 (GLOBE NEWSWIRE) — RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new patent application related to the use of two of RedHill’s proprietary investigational compounds, opaganib (Yeliva®, ABC294640) and RHB-107 (upamostat)1, for the treatment of solid tumor cancers. The patent is expected to extend IP protection for the combination until 2036.
Findings from a recent pre-clinical study evaluating the antitumor effect of opaganib and RHB-107 on cholangiocarcinoma (also known as bile duct cancer) patient-derived xenografts demonstrated that treatment with opaganib and RHB-107, individually and in combination, resulted in tumor regression. Moreover, the combination of both drugs was found to be more potent and well tolerated in the animal models. These findings were presented at the American Association for Cancer Research (AACR) annual meeting earlier this year2.
“It is becoming increasingly evident that cancers are dependent on a number of altered molecular pathways and can develop diverse mechanisms of resistance to therapy with single agents,” said Danielle T. Abramson, Ph.D., VP, Intellectual Property & Research at RedHill. “This application is part of a growing patent portfolio that expands patent protection for our oncology program through 2036. We are very pleased with the additional IP protection for the novel combination of opaganib and RHB-107, which follows promising findings on the potent synergistic antitumor activity of this combination.”
RedHill is conducting a Phase 2a study evaluating the activity of opaganib in advanced, unresectable intrahepatic, perihilar and extrahepatic cholangiocarcinoma (NCT03377179). Enrollment has been completed for the first cohort of 39 patients, evaluating the activity of orally-administered opaganib as a stand-alone treatment. Preliminary data from this cohort indicated a signal of activity in a number of subjects with advanced cholangiocarcinoma, and in light of these data, input from key opinion leaders and preclinical research that had been conducted at Mayo Clinic, RedHill initiated enrollment for a second cohort, evaluating opaganib in combination with hydroxychloroquine, an anti-autophagy agent. Given the encouraging pre-clinical data, RedHill plans to add an additional cohort to the ongoing Phase 2a study in cholangiocarcinoma, evaluating opaganib in combination with RHB-107, subject to discussions with the U.S. FDA.
About Opaganib (ABC294640, Yeliva®)Opaganib, a new chemical entity, is a proprietary, first-in-class, orally-administered, sphingosine kinase-2 (SK2) selective inhibitor with demonstrated dual anti-inflammatory and antiviral activity that targets a host cell component, potentially minimizing the likelihood of viral resistance. Opaganib has also shown anticancer activity and has the potential to target multiple oncology, viral, inflammatory and gastrointestinal indications.
Opaganib received Orphan Drug designation from the U.S. FDA for the treatment of cholangiocarcinoma and is being evaluated in a Phase 2a study in advanced cholangiocarcinoma and in a Phase 2 study in prostate cancer. Opaganib is also being evaluated in a global Phase 2/3 study and a U.S. Phase 2 study for the treatment of severe COVID-19.
Preclinical data have demonstrated both anti-inflammatory and antiviral activities of opaganib, with the potential to reduce inflammatory lung disorders, such as pneumonia, and mitigate pulmonary fibrotic damage. Opaganib demonstrated potent antiviral activity against SARS-CoV-2, the virus that causes COVID-19, completely inhibiting viral replication in an in vitro model of human lung bronchial tissue. Additionally, preclinical in vivo studies3 have demonstrated that opaganib decreased fatality rates from influenza virus infection and ameliorated Pseudomonas aeruginosa-induced lung injury by reducing the levels of IL-6 and TNF-alpha in bronchoalveolar lavage fluids.
Opaganib was originally developed by U.S.-based Apogee Biotechnology Corp. and completed multiple successful preclinical studies in oncology, inflammation, GIVE, and radioprotection models, as well as a Phase 1 clinical study in cancer patients with advanced solid tumors and an additional Phase 1 study in multiple myeloma.
Under a compassionate use program, patients with COVID-19 (as classified by the WHO ordinal scale) were treated with opaganib in a leading hospital in Israel. Data from the treatment of these first patients with severe COVID-19 with opaganib have been published2. Analysis of treatment outcomes suggested substantial benefit to patients treated with opaganib under compassionate use in both clinical outcomes and inflammatory markers as compared to a retrospective matched case-control group from the same hospital. All patients in the opaganib-treated group were discharged from hospital on room air without requiring intubation and mechanical ventilation, whereas 33% of the matched case-control group required intubation and mechanical ventilation. Median time to weaning from high-flow nasal cannula was reduced to 10 days in the opaganib-treated group, as compared to 15 days in the matched case-control group.
The development of opaganib has been supported by grants and contracts from U.S. federal and state government agencies awarded to Apogee Biotechnology Corp., including from the NCI, BARDA, the U.S. Department of Defense and the FDA Office of Orphan Products Development.
The ongoing studies with opaganib are registered on www.ClinicalTrials.gov, a web-based service by the U.S. National Institute of Health, which provides public access to information on publicly and privately supported clinical studies.
About RHB-107 (upamostat)RHB-107 is a proprietary, first-in-class, orally-administered potent inhibitor of several serine proteases with demonstrated antiviral and potential tissue-protective effects. This combined antiviral and potential tissue-protective action make RHB-107 a strong candidate for evaluation as a treatment for COVID-19. A U.S. Phase 2/3 study with RHB-107 in an outpatient setting is planned to be initiated later this year. In addition, RHB-107 has potential in targeting cancer, inflammatory lung diseases and gastrointestinal diseases, and has undergone several Phase 1 studies and two Phase 2 studies, demonstrating its clinical safety profile in over 300 patients. RedHill acquired the exclusive worldwide rights to RHB-107, excluding China, Hong Kong, Taiwan and Macao, from Germany’s Heidelberg Pharmaceuticals (formerly WILEX AG) for all indications.
About RedHill BiopharmaRedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs, Movantik® for opioid-induced constipation in adults with non-cancer pain4, Talicia® for the treatment of Helicobacter pylori (H. pylori) infection in adults5, and Aemcolo® for the treatment of travelers’ diarrhea in adults6. RedHill’s key clinical late-stage investigational development programs include: (i) RHB-204, with a planned Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) infections; (ii) opaganib (Yeliva®), a first-in-class SK2 selective inhibitor targeting multiple indications with a Phase 2/3 program for COVID-19 and Phase 2 studies for prostate cancer and cholangiocarcinoma ongoing; (iii) RHB-104, with positive results from a first Phase 3 study for Crohn’s disease; (iv) RHB-102 (Bekinda®), with positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; (v) RHB-107, a Phase 2-stage first-in-class, serine protease inhibitor, targeting cancer and inflammatory gastrointestinal diseases and is also being evaluated for COVID-19 and (we) RHB-106, an encapsulated bowel preparation. More information about the Company is available at www.redhillbio.com. This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties, include without limitation, the risk that the Company will not succeed in adding a third cohort to its ongoing Phase 2a clinical study in patients suffering from advanced cholangiocarcinoma, in which the Company expects to evaluate the efficacy of opaganib in combination with RHB-107; as well as other risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company’s research, manufacturing, pre-clinical studies, clinical trials, and other therapeutic candidate development efforts, and the timing of the commercial launch of its commercial products and ones it may acquire or develop in the future; (ii) the Company’s ability to advance its therapeutic candidates into clinical trials or to successfully complete its pre-clinical studies or clinical trials or the development of a commercial companion diagnostic for the detection of MAP; (iii) the extent and number and type of additional studies that the Company may be required to conduct and the Company’s receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company’s therapeutic candidates and commercial products; (v) the Company’s ability to successfully commercialize and promote Talicia®, and Aemcolo® and Movantik®; (we) the Company’s ability to establish and maintain corporate collaborations; (vii) the Company’s ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of the Company’s therapeutic candidates and the results obtained with its therapeutic candidates in research, pre-clinical studies or clinical trials; (ix) the implementation of the Company’s business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and commercial products and its ability to operate its business without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xii) estimates of the Company’s expenses, future revenues, capital requirements and needs for additional financing; (xiii) the effect of patients suffering adverse experiences using investigative drugs under the Company’s Expanded Access Program; (xiv) competition from other companies and technologies within the Company’s industry; and (xv) the hiring and maintaining employment of executive managers. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 20-F filed with the SEC on March 4, 2020. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise unless required by law.
1 Opaganib (Yeliva®, ABC294640) and RHB-107 (upamostat, WX-671) are investigational new drugs, not available for commercial distribution.2 Faizal ZA et al. Abstract 3078: Effects of upamostat and opaganib on cholangiocarcinoma patient derived xenografts. Cancer Res August 15 2020 (80) (16 Supplement) 3078; DOI: 10.1158/1538-7445.AM2020-30783 Xia C. et al. Transient inhibition of sphingosine kinases confers protection to influenza A virus infected mice. Antiviral Res. 2018 Oct; 158:171-177. Ebenezer DL et al. Pseudomonas aeruginosa stimulates nuclear sphingosine-1-phosphate generation and epigenetic regulation of lung inflammatory injury. Thorax. 2019 Jun;74(6):579-591.4 Full prescribing information for Movantik® (naloxegol) is available at: www.Movantik.com.5 Full prescribing information for Talicia® (omeprazole magnesium, amoxicillin and rifabutin) is available at: www.Talicia.com.6 Full prescribing information for Aemcolo® (rifamycin) is available at: www.Aemcolo.com.
Biden has proposed raising the capital gains tax rate from 20% to 39.6% for those making over $1 million, which would represent a big blow to the asset management industry. Other tax hikes he has put forward include increasing the statutory corporate income tax rate from 21% to 28%. Biden was leading in key Midwestern states in the race for the White House as votes were being counted on Wednesday afternoon, but President Donald Trump’s Republican Party was poised to keep control of the Senate even as Democrats retained their majority in the House of the Representatives.
(Bloomberg) — Skyrocketing bullion prices helped Barrick Gold Corp. generate record amounts of cash — and shareholders are getting rewarded with another dividend hike.The world’s second-largest gold producer spun out $1.3 billion of free cash flow in the third quarter, prompting the company to hike its quarterly payout for a third time in the past year. Barrick reported quarterly earnings and revenue that topped analysts’ estimates on Thursday, as surging bullion prices helped offset the impacts of the coronavirus pandemic on its business.“In the face of unprecedented challenges we have succeeded in beating our earnings consensus, reinforcing our 10-year plan and capitalizing on the gold price to maintain an industry-leading balance sheet,” Chief Executive Officer Mark Bristow said in the company’s earnings report.Gold surged to record heights above $2,000 an ounce in August, helping lift miners’ fortunes. Barrick raised its dividend almost 13% to 9 cents a share, joining rivals Newmont Corp., AngloGold Ashanti Ltd. and Agnico Eagle Mines Ltd. in boosting quarterly payouts. Barrick’s dividend has doubled since mid-2019.Bristow said the 9-cent dividend is “sustainable” and the Toronto-based company still plans to announce a new policy for returning capital to shareholders next year.“At the same time, I’m more conservative than most,” Bristow said in a phone interview. “I’ve always been like that.”Barrick also reduced its debt net of cash by 71% to $417 million, and the company said it has no significant maturities until 2033.Barrick rose 2.9% to $28.21 at 8 a.m. in early U.S. trading. The shares climbed 48% this year through Wednesday’s close in New York, tracking the gains of a Bloomberg Intelligence index of senior gold miners.Get MoreBarrick reported adjusted earnings of 41 cents a share in the third quarter, beating the 33-cent average estimate of 18 analysts in a Bloomberg survey. Revenue jumped 32% to $3.54 billion, the highest since Barrick completed its merger with Randgold Resources Ltd. in January 2019.For additional details on the news, click here.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Wall Street legend Whitney Tilson says there’s a huge new tech trend coming – and he’s revealing his #1 pick for free.
Tell that to Jack Ma. Corporate China’s shiniest star was just days away from seeing his Ant Group list on the stock market in a record $37 billion deal, when he chose to launch a blistering public attack on the country’s financial watchdogs and banks. The regulatory system was stifling innovation and must be reformed to fuel growth, billionaire Ma told a summit in Shanghai on Oct. 24 attended by the great and the good of China’s financial, regulatory and political establishment.
I recently had a conversation with a colleague about retirement and was told I’m saving too much! My wife and I are both 57 and have been aggressive savers ever since my brother, an institutional retirement financial expert, told us to max out our savings when we were 25 years old.
Global research firm just identified a stock with the potential to “crush Zoom’s gains.” Click here to see which stock they’re recommending.
Amazon Inc (NASDAQ: AMZN) CEO Jeff Bezos has offloaded $3 billion worth of the e-commerce company’s shares this week, according to filings with the U.S. Securities and Exchange Commission on Wednesday.What Happened: Bezos’s beneficial ownership filings show that a total of one million common stock shares were sold on Monday and Tuesday. The transactions were part of Amazon’s 10b5-1 trading plan — a strategy that allows company insiders to sell stocks at preset parameters.With the recent sale, Bezos has sold off more than $10 billion worth of Amazon shares this year, but still holds over 10% stake in the tech company.In August, the billionaire entrepreneur and investor sold off billion worth of shares in the price range of $3,102.85 and 3,183.26. Bezos had earlier sold shares worth about $4.1 billion between January and February.Why Does It Matter: Bezos, in 2018, disclosed that he sells about $1 billion worth of Amazon shares annually to fund Blue Origin LLC — the aerospace equipment manufacturing company he founded in 2000. In 2019, Bezos had sold Amazon common stock worth around $2.8 billion.Benzinga’s Take: Bezos isn’t selling his shares on the open market, and 10b5-1 sales like these are common for the Amazon CEO to fund other ventures of his interests, including Blue Origin and philanthropic work. This event doesn’t necessarily reflect Bezos’s views on Amazon’s future stock performance.Price Action: AMZN closed 6.32% higher at $3,241.16.Photo courtesy of Seattle City Council via FlickrSee more from Benzinga * Click here for options trades from Benzinga * Spotify Rolls Out Standalone Streaming On Apple Watch App: TechCrunch * A Chinese Company’s Stock Is Surging — Thanks To Trump(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Alibaba Holding Group said its second quarter revenues jumped more than 30% from last year to a U.S. dollar equivalent of $22.8 billion.
GM earnings beat after it reported strong North American truck demand in Q3, following a pandemic hit in prior quarters.
Tesla Inc (NASDAQ: TSLA) has received an order for 150 units of its Semi electric truck from a Mississauga, Canada-based trucking conglomerate.What Happened: Pride Group Enterprises announced Wednesday in a statement that it had placed a deposit to secure the initial units and build slots and would further consider purchasing up to 500 trucks.”We believe that electrification is the way of the future as we work together across multiple industries to reduce our carbon footprint,” Pride Group CEO Sam Johal said.”Pride Group Enterprises’ vision is to invest in facilities that will support charging, full-service maintenance and a consistent supply of electric trucks on North American highways.”The company said it was busy investing in the necessary infrastructure needed for parking, charging and maintenance at its locations to support the arrival of the all-electric class 8 trucks.Why It Matters: Privately-held Pride Group has 12 locations in the United States and Canada. The 300-employee company had a five-year growth rate of 2,365% as of September last year, according to Canadian Business.Pride Group’s order is larger than the 130 units ordered by Walmart Inc (NYSE: WMT) in Canada. Tesla CEO Elon Musk said this summer that it was time to bring the Semi truck to “volume production.” The company had unveiled two concept vehicles in November 2017 with production slated to commence in 2021 at the time. Price Action: Tesla shares closed nearly 0.7% lower at $420.98 on Wednesday and gained 0.34% in the after-hours session.Photo courtesy: Tesla See more from Benzinga * Click here for options trades from Benzinga * Tesla Was A Month Away From Bankruptcy Ahead Of Model 3 Rollout, Says Musk * Tesla FSD Beta Is Next Rolling Out In Canada, Norway, Musk Says(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
There’s still time to benefit from 2020’s IRA contribution limits. And odds are that you haven’t put in the maximum allowed yet.
The clock just started on the biggest financial event in 20 years. Fortunes will be made and lost. Here’s how to prepare – before 2020 comes to an end
Joe Biden is closer to securing the U.S. presidency; stock futures rise and the tech sector leads on the potential for a divided U.S. government; Qualcomm soars after an earnings beat; the Fed issues a decision on interest rates.
Chipmaking giant Intel has taken steps to right its ship after a rough 2019 that rocked INTC stock. But is Intel stock a buy right now? Here’s what its earnings and stock chart show.
BYD joined fellow China electric car stocks Nio, Xpeng Motors and Li Auto in reporting robust October sales.
Compare 2020 top lenders to get matched with lenders curated for your needs in 2 min. A+ Rating with BBB. Over 15 million served since 2005. 2.39% APR
Shares of Teva Pharmaceutical Industries Ltd. gained 0.4% in premarket trading on Thursday after it beat revenue expectations for the third quarter. The Israeli drug maker had a loss of $4.3 billion, or $3.97 per share, in the third quarter of 2020, compared to a loss of $307 million, or 29 cents per share, in the same quarter a year ago. Adjusted earnings per share were 58 cents, matching the FactSet consensus. Teva had revenue of $3.9 billion for the quarter, down from $4.1 billion in the same period a year ago. The FactSet consensus was about $4.0 billion. The company attributed the decline to lower sales in its generic and over-the-counter businesses, as well as for Copaxone, its flagship multiple sclerosis product, which reported a 13% decline in sales, to $236 million in North America. It also reported lower demand for certain therapies as a result of the COVID-19 pandemic. Sales of Parkinson’s disease drug Austedo jumped 60% to $168 million for the quarter in North America. Teva’s stock is down 2.8% for the year, compared with the S&P 500 , which has gained 6.6%.
Alibaba earnings topped fiscal Q2 views, but revenue growth was a little light. Alibaba stock fell in a wild week for the China e-commerce giant.
Bristol-Myers boosted its 2020 profit outlook after a solid third quarter that included a 75% surge in group revenues following last year’s $74 billion takeover of Celgene.
If you owe less than $625,000 on your home and have no missed payments in 3 months, you better read this.
Why did Hyliion stock rise up 2.5% Wednesday while stock in commercial electric van maker (WKHS) (WKHS) dropped 8.2%? What’s more, shares of EV truck marker (RIDE) (RIDE) rose 5.4% Wednesday while shares of electric sport utility maker (FSR) (FSR) dropped 6.3%. The trading does make sense, sort of, if investors look at it over a longer time horizon, consider Wall Street sentiment, and parse the industry by end markets served by each EV company.
Apple has been an American success story several times over with the Mac, iPod, iPhone and other inventions. But is Apple stock a buy now? Here’s what its stock chart and earnings show.
Cronos Group Inc. shares [ rose 6% in premarket trade Thursday, after the Canadian cannabis company posted better-than-expected earnings for the third quarter and named a new CEO. Cronos said it had a net income of $68.464 million, or 19 cents a share, in the quarter, down from $604.128 million, or $1.62 a share, in the year-earlier period. Revenue net of excise taxes came to $11.4 million, up from $5.8 million a year ago. The FactSet consensus was for a loss of 6 cents a share and revenue of $11.1 million. Earnings in the year-earlier period were buoyed by a $632.5 million gain on a revaluation of derivative liabilities. That number came to $105.3 million in the 2020 third quarter. The company named Kurt Schmidt as its new president and CEO, replacing Mike Gorenstein who has been appointed executive chairman. Schmidt is a former CEO of Blue Buffalo Co. Ltd. and has done stints at Nestle and Kraft Foods. “During the third quarter of 2020, because of the effects from COVID-19 in the U.S. a significant number of the Company’s retail customers continued to be challenged by permanent and temporary store closings,” the company said. Shares have fallen 28% in the year to date, while the Cannabis ETF has fallen 27% and the S&P 500 has gained 6.6%.
RedHill Biopharma Ltd (ADR), Opaganib, NASDAQ:RDHL, Patent, Clinical trial, USPTO
World news – THAT – RedHill Biopharma Receives U.S. Patent Allowance Covering Opaganib and RHB-107 Combination